APVO - CIK 0001671584
Aptevo Therapeutics Inc. (APVO) reported net income of -$25.97M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$25.97M | -7.6% |
| FY 2024 | -$24.13M | -38.6% |
| FY 2023 | -$17.41M | -316.9% |
| FY 2022 | $8.03M | +128.2% |
| FY 2021 | -$28.46M | -60.3% |
| FY 2020 | -$17.75M | +56.1% |
| FY 2019 | -$40.45M | +24.7% |
| FY 2018 | -$53.69M | -870.0% |
| FY 2017 |
Aptevo Therapeutics Inc. (APVO) reported net income of -$25.97M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2015 and fiscal 2025, Aptevo Therapeutics Inc.'s net income grew from -$59.32M to -$25.97M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $6.97M |
| +106.2% |
| FY 2016 | -$112.42M | -89.5% |
| FY 2015 | -$59.32M | - |